RxDoctor Payments Data

Micah Eimer, MD

Cardiovascular Disease · Glenview, ILNPI 1396709093

Payments from drug & device makers

$36,796in general payments, 2019–2025

Across 9 payments — averaging $4088.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nascent Surgical LLC$25K
  • Pleural Dynamics Inc.$11K
  • Abbott$191
  • Edwards Lifesciences$172
  • E.r. Squibb & Sons, L.L.C.$128
  • Ortho-clinical Diagnostics, Inc.$81
  • plus $27 from 1 others

What the payments were for

  • Food & beverage$599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Nascent Surgical LLC1$25,000
Pleural Dynamics Inc.1$11,197
Abbott3$191
Edwards Lifesciences1$172
E.r. Squibb & Sons, L.L.C.1$128
Ortho-clinical Diagnostics, Inc.1$81
Pfizer1$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,796 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$504,297
Medicare patients
3,233
Services billed
7,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban488$686,596
XareltoRivaroxaban161$256,148
CamzyosMavacamten21$167,225
Repatha SureclickEvolocumab143$97,793
JardianceEmpagliflozin43$66,595
EntrestoSacubitril/Valsartan34$58,457
Praluent PenAlirocumab66$36,133
FarxigaDapagliflozin Propanediol25$27,858
MultaqDronedarone Hcl13$18,512
Metoprolol Succinate846$14,268
BrilintaTicagrelor13$13,065
NexlizetBempedoic Acid/Ezetimibe12$10,789
Rosuvastatin Calcium737$9,339
CrestorRosuvastatin Calcium12$8,181
Repatha SyringeEvolocumab15$8,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$686,596488 claims
E.r. Squibb & Sons, L.L.C.Camzyos$128$167,22521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →